{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:32:09Z","timestamp":1773160329655,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masarykova Univerzita","doi-asserted-by":"publisher","award":["MUNI\/A\/1063\/2016"],"award-info":[{"award-number":["MUNI\/A\/1063\/2016"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T08:52:53Z","timestamp":1499935973000},"page":"148-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats"],"prefix":"10.1016","volume":"123","author":[{"given":"Katerina","family":"Horska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Ruda-Kucerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Drazanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Karpisek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Demlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kasparek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Kotolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.06.003_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2014.12.023","article-title":"Obesity, adipokines and neuroinflammation","volume":"96","author":"Aguilar-Valles","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ajhg.2013.01.001","article-title":"Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors","volume":"92","author":"Andreassen","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.metabol.2014.10.016","article-title":"From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century","volume":"64","author":"Bl\u00fcher","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib6","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1038\/tp.2015.161","article-title":"A\u00a0potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Cai","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2478\/s13380-012-0045-6","article-title":"Prenatal infection, maternal immune activation, and risk for schizophrenia","volume":"3","author":"Canetta","year":"2012","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.28.1_supplement.1107.5","article-title":"Dopamine D2 receptors regulate leptin and IL-6 in 3T3 L1 adipocytes (1107.5)","volume":"28","author":"Cuevas","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.pbb.2014.06.004","article-title":"Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats","volume":"124","author":"De Santis","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/schbul\/sbw028","article-title":"Somatic Comorbidity in schizophrenia: some possible biological mechanisms across the life span","volume":"42","author":"Dieset","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1741-7015-10-92","article-title":"Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits","volume":"10","author":"Ebdrup","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2015.05.004","article-title":"Metabolic syndrome in drug-na\u00efve and drug-free patients with schizophrenia and in their siblings","volume":"166","author":"Enez Darcin","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/0269881115602490","article-title":"Antipsychotic-induced metabolic effects in the female rat: direct comparison between long-acting injections of risperidone and olanzapine","volume":"29","author":"Ersland","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","article-title":"Olanzapine depot exposure in male rats: dose-dependent lipogenic effects without concomitant weight gain","volume":"25","author":"Ferno","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000441521","article-title":"Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications","volume":"2","author":"Fonseka","year":"2016","journal-title":"Mol. Neuropsychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2337\/db06-1656","article-title":"Visceral fat adipokine secretion is associated with systemic inflammation in obese humans","volume":"56","author":"Fontana","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/db14-1176","article-title":"Ghrelin is a novel regulator of GLP-1 secretion","volume":"64","author":"Gagnon","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1748-1716.2007.01779.x","article-title":"Role of interleukin-6 signalling in glucose and lipid metabolism","volume":"192","author":"Glund","year":"2008","journal-title":"Acta Physiol. oxf. Engl."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0269881115602952","article-title":"Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female sprague-dawley rats","volume":"29","author":"Hegedus","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/0269881117691466","article-title":"Depot risperidone-induced adverse metabolic alterations in female rats","author":"Horska","year":"2017","journal-title":"J.\u00a0Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00213-005-0081-9","article-title":"Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats","volume":"182","author":"Kalinichev","year":"2005","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2004.01.012","article-title":"Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach","volume":"119","author":"Kamegai","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.12423","article-title":"Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms","volume":"17","author":"Kanoski","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0447.2011.01716.x","article-title":"Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder","volume":"124","author":"Kasteng","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MOL.0000000000000307","article-title":"Lipidology, cardiovascular risk, and schizophrenia","volume":"27","author":"Kritharides","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5507\/bp.2014.060","article-title":"The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. a review","volume":"159","author":"Kucerova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00210-010-0499-4","article-title":"Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes","volume":"381","author":"Lauressergues","year":"2010","journal-title":"Naunyn. Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib34","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00125-016-3965-9","article-title":"Glucagon is the key factor in the development of diabetes","volume":"59","author":"Lee","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0269881111431622","article-title":"The metabolic syndrome in schizophrenia: is inflammation a contributing cause?","volume":"26","author":"Leonard","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib36","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.2337\/db06-S020","article-title":"Glucagon-like peptide 1 secretion by the L-cell - the view from within","volume":"55","author":"Lim","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2015.11.011","article-title":"A\u00a0systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia","volume":"170","author":"Malan-M\u00fcller","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.schres.2016.04.036","article-title":"Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: a one-year outcome study","volume":"174","author":"Malla","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib40","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.neuropharm.2011.01.009","article-title":"To poly(I: C) or not to poly(I: C): advancing preclinical schizophrenia research through the use of prenatal immune activation models","volume":"62","author":"Meyer","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pharmthera.2011.06.003","article-title":"Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative\/cognitive symptoms and beyond","volume":"132","author":"Meyer","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00441-013-1692-9","article-title":"Leading compounds for the validation of animal models of psychopathology","volume":"354","author":"Micale","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbi.2014.06.013","article-title":"The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model","volume":"42","author":"Missault","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"Muller","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psc.2408","article-title":"Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21","volume":"18","author":"M\u00fcller","year":"2012","journal-title":"J.\u00a0Pept. Sci. Off. Publ. Eur. Pept. Soc."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib47","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4088\/JCP.15m10467","article-title":"Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia","volume":"77","author":"Nasrallah","year":"2016","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib48","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in\u00a0vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib49","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A\u00a0multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/acps.12692","article-title":"Increasing support for association between immune system and severe mental illness - need to find the underlying mechanisms","volume":"135","author":"Ole","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib51","first-page":"572848","article-title":"The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors","volume":"2012","author":"Panariello","year":"2012","journal-title":"J.\u00a0Obes."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2014.07.045","article-title":"Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis","volume":"159","author":"P\u00e9rez-Iglesias","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.dci.2016.06.006","article-title":"Leptin as immune mediator: interaction between neuroendocrine and immune system","volume":"66","author":"Procaccini","year":"2017","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0004867415575380","article-title":"Increased serum fibroblast growth factor 21 levels in patients with schizophrenia","volume":"49","author":"Qing","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00125-016-3906-7","article-title":"Renaissance of leptin for obesity therapy","volume":"59","author":"Quarta","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib56","series-title":"Prenatal and Postnatal Determinants of Development, Neuromethods","first-page":"263","article-title":"Studies on the effects prenatal immune activation on postnatal behavior: models of developmental origins of schizophrenia","author":"Ratnayake","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pharmthera.2015.01.001","article-title":"The poly(I: C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery","volume":"149","author":"Reisinger","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib58","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3945\/jn.114.206029","article-title":"Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling","volume":"145","author":"Ronveaux","year":"2015","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib59","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in\u00a0vitro","volume":"450","author":"Sarvari","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib60","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","article-title":"Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review","volume":"34","author":"Sentissi","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","article-title":"GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharep.2014.09.007","article-title":"Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity","volume":"67","author":"Sobi\u015b","year":"2015","journal-title":"Pharmacol. Rep. P. R."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib65","article-title":"Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment","author":"Steen","year":"2016","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A\u00a0randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? a systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib68","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s00213-014-3466-9","article-title":"Ghrelin receptor antagonism of morphine-induced accumbens dopamine release and behavioral stimulation in rats","volume":"231","author":"Sustkova-Fiserova","year":"2014","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin. Neurosci"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40264-015-0298-4","article-title":"Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis","volume":"38","author":"Takeuchi","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib71","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib72","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1210\/jc.2004-0603","article-title":"Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in\u00a0vitro","volume":"89","author":"Trujillo","year":"2004","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1155\/EDR.2001.217","article-title":"Leptin and its relation to obesity and insulin in the SHR\/N-corpulent rat, a model of type II diabetes mellitus","volume":"2","author":"Velasque","year":"2001","journal-title":"Int. J. Exp. Diabetes Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2010.05.060","article-title":"Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state","volume":"1350","author":"Victoriano","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/14796708.2.2.153","article-title":"Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors","volume":"2","author":"Wadenberg","year":"2007","journal-title":"Future Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2006.07.008","article-title":"Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties","volume":"546","author":"Wood","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-013-3193-7","article-title":"Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia","volume":"229","author":"Yan","year":"2013","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.06.003_bib78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/15622975.2016.1165865","article-title":"Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics","volume":"17","author":"Yang","year":"2016","journal-title":"World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib79","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.psyneuen.2013.07.010","article-title":"The role of ghrelin signalling in second-generation antipsychotic-induced weight gain","volume":"38","author":"Zhang","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib80","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.06.003_bib81","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.neuropharm.2011.02.022","article-title":"Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats","volume":"62","author":"Zhang","year":"2012","journal-title":"Neuropharmacol. Schizophr."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T14:15:20Z","timestamp":1655561720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817302733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":81,"alternative-id":["S0028390817302733"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.003","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}